根据最新提交给美国证券交易委员会（SEC）的文件，Phio Pharmaceuticals Corp（简称：Phio Pharmaceuticals）在其临床试验中取得积极进展。文件显示，在所有5个剂量递增队列中，均未观察到任何严重不良事件或毒性反应。
这一结果标志着公司在药物安全性方面迈出重要一步，为后续临床开发奠定坚实基础。研究数据的稳健性进一步验证了其候选疗法的潜在耐受性。
分析指出，无严重安全性问题的发现，有望加速Phio Pharmaceuticals推进相关治疗方案的研发进程，并为投资者带来信心支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.